Laquinimod therapy in multiple sclerosis: a comprehensive review

Channa Kolb-Sobieraj, Sahil Gupta, Bianca Weinstock-Guttman, Channa Kolb-Sobieraj, Sahil Gupta, Bianca Weinstock-Guttman

Abstract

Introduction: Multiple sclerosis (MS) is considered an autoimmune disease with inflammatory and neurodegenerative underlying processes that affect the central nervous system. The available disease-modifying therapies (DMTs) approved to treat MS have only shown partial benefit in controlling the disease progression, primarily impeding its inflammatory component, while the parenteral administration of most of these therapies has shown to affect patient compliance. Laquinimod is a promising new oral drug recently evaluated in a third phase III clinical trial that demonstrated beneficial effects in delaying disease progression and preventing brain atrophy, suggesting a potential neuroprotective effect and a favorable safety profile.

Areas covered: This is a comprehensive review covering clinical efficacy and safety data obtained from two phase III clinical trials, as well as the presumed beneficial mechanism of action, of laquinimod. This article also provides a short overview of the oral DMTs recently approved for the treatment of relapsing MS, as well as challenges that still remain to be overcome to fully control the relentless course of MS.

Conclusion: Laquinimod has been shown to have a novel immunomodulatory and potential neuroprotective mechanism of action as suggested from animal models and in vitro experimental data. Phase III clinical trials ALLEGRO (Clinicaltrials.gov #NCT00509145) and BRAVO (Clinicaltrials.gov #NCT00605215) have demonstrated clinical efficacy and tolerability, while the third phase III study is currently evaluating the safety and efficacy of laquinimod at a higher dosage. Emerging oral treatments like laquinimod will provide new options for patients to consider that can lead to better patient adherence and improved outcomes.

Keywords: Clinical trials; Disease modifying therapies; Laquinimod; Multiple sclerosis; Neurology; Neuroprotection.

Figures

Fig. 1
Fig. 1
The figure illustrates the mechanism of action of laquinimod and its presumed site of action. IFN interferon, IL interleukin, TNF tumor necrosis factor

References

    1. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–1009. doi: 10.1056/NEJMoa1104318.
    1. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000;54:1726–1733. doi: 10.1212/WNL.54.9.1726.
    1. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive Ms: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000;54:1734–1741. doi: 10.1212/WNL.54.9.1734.
    1. Tan IL, Lycklama a Nijeholt GJ, Polman CH, Ader HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler. 2000;6:99–104. doi: 10.1177/135245850000600208.
    1. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-Dihydro-4-Hydroxy-2-Oxo-3-Quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem. 2004;47:2075–2088. doi: 10.1021/jm031044w.
    1. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immuno regulator laquinimod (Abr-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163–172. doi: 10.1016/S0165-5728(02)00225-4.
    1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85:299–302. doi: 10.1016/S0092-8674(00)81107-1.
    1. Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol. 2005;18:225–230. doi: 10.1097/01.wco.0000169737.99040.31.
    1. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173–179. doi: 10.1016/j.jns.2011.02.019.
    1. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (Abr-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 Cytokine Tgf-Beta in Lewis Rats. J Neuroimmunol. 2004;156:3–9. doi: 10.1016/j.jneuroim.2004.02.016.
    1. Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133–143. doi: 10.1016/j.jneuroim.2010.07.009.
    1. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221:87–94. doi: 10.1016/j.jneuroim.2010.02.010.
    1. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. doi: 10.1146/annurev.neuro.24.1.677.
    1. Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012;180:267–274. doi: 10.1016/j.ajpath.2011.09.037.
    1. Suhs K-W. Effects of laquinimod on axon degeneration in autoimmune optic neuritis. Mult Scler 2007;13:S7–S273.
    1. Thone J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011;7:365–370. doi: 10.1517/17425255.2011.556618.
    1. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64:987–991. doi: 10.1212/01.WNL.0000154520.48391.69.
    1. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16:1360–1366. doi: 10.1177/1352458510378127.
    1. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085–2092. doi: 10.1016/S0140-6736(08)60918-6.
    1. Vollmer T, Soelberg Sorensen P, Arnold DL, on behalf of the BRAVO study group. A placebo-controlled and active comparator phase III trial (Bravo) for relapsing-remitting multiple sclerosis. Amsterdam, Netherlands: 5th joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; 2011.
    1. . The efficacy and safety and tolerability of laquinimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO). (last accessed April 9, 2014).
    1. Waubant E. Overview of treatment options in multiple sclerosis. J Clin Psychiatry. 2012;73:e22. doi: 10.4088/JCP.11006nr2c.
    1. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010;CD004678.
    1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG)’. Ann Neurol. 1996;39:285–294. doi: 10.1002/ana.410390304.
    1. IFNB Multiple Sclerosis Study Group Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial. Neurology. 1993;43:655. doi: 10.1212/WNL.43.4.655.
    1. Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf. 2013;5:37–47. doi: 10.2147/DHPS.S28822.
    1. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10:1026–1034. doi: 10.1016/S1474-4422(11)70228-9.
    1. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. doi: 10.1056/NEJMoa0909494.
    1. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from transforms. J Neurol. 2013;260:2023–2032. doi: 10.1007/s00415-013-6932-0.
    1. Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–15. Expert Opin Pharmacother. 2010;11(10):1777–81.
    1. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303. doi: 10.1056/NEJMoa1014656.
    1. Kappos L, Comi G, Confavreux C. The efficacy and safety of teriflunomide in patients with relapsing MS: results from tower, a phase III, placebo-controlled study. Lyon, France: 28th Congress of the European committee for research and treatment in multiple sclerosis (ECTRIMS); 2012.
    1. . A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE). (last accessed April 9, 2014).
    1. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (Dimethyl Fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the define study. J Neurol. 2013;260:2297–2305. doi: 10.1007/s00415-013-6954-7.
    1. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (Dimethyl Fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the confirm study. J Neurol. 2013;260:2286–2296. doi: 10.1007/s00415-013-6968-1.
    1. Barkhof F, Calabresi P, Miller D, Reingold S. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(256–266):39.
    1. Rammohan K, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology. 2010;74:s47–s53. doi: 10.1212/WNL.0b013e3181c97f89.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir